The US therapeutic plasma exchange market is projected to reach USD 243 million by 2025 from USD 178 million in 2020, at a CAGR of 6.3% during the forecast period. Growth in this market is driven by the rising prevalence of chronic diseases and technological advancements. However, factors such as the high cost of apheresis devices and therapeutic plasma exchange procedures and installation of apheresis devices through a rental model are expected to restrain the growth of this market to a certain extent during the forecast period.
Prominent players in the US therapeutic plasma exchange market include Terumo BCT, Inc. (US), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Asahi Kasei Medical Co. Ltd. (Japan), B. Braun Melsungen AG (Germany), Baxter International Inc. (US), Cerus Corporation (US), Kaneka Corporation (Japan), Kawasumi Laboratories, Inc. (Japan), Nikkiso Co., Ltd. (Japan), Miltenyi Biotec (Germany), Medica S.p.A. (Italy), Medicap Clinic GmbH (Germany), and Infomed (Switzerland). These companies are focusing on increasing their presence in the high-growth markets through both organic as well as inorganic growth strategies such as product launches, acquisitions, partnerships, agreements, collaborations, and expansions.
To know about the assumptions considered for the study download the pdf brochure
Terumo BCT accounted for largest share of the US therapeutic plasma exchange market in 2019. The company is known for its diversified product offerings in the field of plasma exchange. Terumo’s key products include Spectra Optia and COBE Spectra; these products are widely adopted by blood centers, blood component providers, hospitals, and transfusion centers for therapeutic plasma exchange purposes. The company has a significant global footprint owing to its strong sales and distribution network. Strong after-sales services such as maintenance and re-installation of instruments give the company a competitive advantage over other players in the therapeutic plasma exchange market.
Fresenius accounted for second largest share of the US therapeutic plasma exchange market in 2019. The company has maintained its leading position in the market through its strong distribution networks across the Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa. The company offers therapeutic plasma exchange systems and related disposables for plasma exchange procedures through its Fresenius Kabi and Fresenius Medical Care business segments.
The company is focusing on expanding its presence in the emerging markets. For instance, in 2016, Fresenius introduced the AmiCORE apheresis device in Malaysia, Thailand, and Vietnam. The company has a strong product portfolio, and its CE-approved products have helped it in further enhancing its presence in the US therapeutic plasma exchange market.
US Therapeutic Plasma Exchange Market by Product (Devices, Consumables) Technology (Centrifugation, Membrane Separation) Procedures & Patients (Guillain Syndrome, Multiple Sclerosis, Cryoglobulinemia), End Users Covid-19 Impact - Forecast To 2025
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE